Palvella Therapeutics Announces First Patient Dosed in Selva Phase 3 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics宣佈在Selva第3期臨床試驗中首位患者接受了Qtorin™ 3.9%雷帕黴素無水凝膠（Qtorin™雷帕黴素）治療微囊性淋巴管畸形。
